
Opinion|Videos|May 28, 2024
CSF Testing and Blood-based Biomarkers in Alzheimer’s Disease
Panelists review the use of CSF and blood-based biomarkers in Alzheimer's disease, discussing the role of tau as a marker of neuronal injury and its utility in staging the progression of Alzheimer's disease.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- Describe the use of CSF and blood-based biomarkers in AD.
- Which biomarkers/histopathological features are associated with different stages of Alzheimer’s disease?
- What are you using in your practice?
- What are the unmet needs?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
The Future of Targeted Therapy in CIDP
2
AHA/ASA Issue New Guideline for Adult Stroke Rehabilitation and Recovery
3
FDA Places RGX-121 Gene Therapy for MPS II on Clinical Hold
4
How the Field Built the First Consensus Clinical Trial Framework for Charcot-Marie-Tooth Disease
5




















